Targeting the Mesenchymal Cancer Cell Phenotype for Therapeutic Gain
Most cancer patients die from malignant metastases, or because the patients have become insensitive to chemotherapy. In this project, we aim to identify and repurpose existing drugs to selectively change the behaviour of aggressive cancer cells into non-invasive and therapy sensitive cancer cells or benign fat cells.
Type the project impact here.
More detailed information
Prof. J.W.M. (John) Martens and prof. S. (Stefan) Sleijfer
Role Erasmus MC: